Major push to grant Aussie workers extra 12-days paid leave per year: 'This is not sick leave'
However, a report into the Costs and Benefits of Implementing a Universal Reproductive Health Leave Entitlement in Australia found the policy would improve mental health and workforce retention. The policy would largely benefit women, but would also cater to men undergoing vasectomies.
'Women represent half of our population, and for most, that comes with menstruation which can bring pain, as well as conditions like endometriosis, IVF, miscarriage, and menopause,' HSU national senior assistant secretary Kate Marshall said.RELATED
Aussie mum painful endo-battle sparks idea for six-figure business: 'Gave up $50,000 savings'
Mark Bouris issues blunt retirement message for young Australians: 'Accept it now'
Woolworths cleared to make major move into $1.9 billion sector: 'Strong price competition'
'By rolling out a universal entitlement of 12 days a year, we will give all workers, particularly women, dignity and agency to be a part of a workforce that doesn't currently reflect our needs."
The 12 days would represent a day each month of the year.
But Marshall said: "This is not sick leave."
'Work can be extremely difficult when you are dealing with pain or reproductive conditions,' she said.
Nearly one million Australians live with endometriosis, a debilitating condition that has no cure.
Kellie Johnson was diagnosed with stage 4 endometriosis in her twenties but has been living with menstrual pain since she first started getting her period.
The 41-year-old Central Coast resident told Yahoo Finance the pain was so severe that she would often throw up or lose consciousness.
Johnson said endometriosis had a huge impact on her career journey, admitting there was a time she 'never spoke' about what she was going through.
'At so many workplaces I've had, I've had to alter the way I work in some way just to try and survive,' she said.
'For example, I've had periods where my endo got really bad so I would be in hospital a lot, so I would take my laptop with me and work from hospital.
'You just worry that people will think that you're being lazy or that you're not taking your job seriously.'
Endometriosis Australia found many people were fearful of raising the issue in their workplace, with one in three passed over for a promotion due to their endometriosis, and one in six losing their jobs.
The group's research found endometriosis was costing the Australian economy $9.7 billion annually due to medical costs, absenteeism and presenteeism.
'I think when you feel like you're struggling with pain all the time, you almost feel like you have to work harder to try and prove yourself,' Johnson said.
The report, released yesterday, highlighted how prevalent the impact of reproductive illness was on the Australian workforce.
Menstrual pain affects more than 50 per cent of working women, and 74 per cent of women aged 45 to 55 reported menopause symptoms, with 17 per cent requiring extended leave.
Vasectomies and hysterectomies are also common, particularly for men and women aged 35 to 44 years.
Miscarriage affects up to one in three women, and 8 per cent of women aged 25–45 undergo IVF annually.
Workers surveyed for the report said they often used sick leave or unpaid time off, with 44 per cent taking unpaid leave when they had symptoms.
This was not out of choice but a lack of leave options.
"By rolling out a universal entitlement of 12 days a year, we will give all workers, particularly women, dignity and agency to be a part of a workforce that doesn't currently reflect our needs," Marshall said.
In 2024, the Queensland government introduced 10 days of paid reproductive leave for the state's public servants.
A concerning 68 per cent of those surveyed said they had not disclosed their condition to their manager.
HSU national secretary Lloyd Williams said reproductive needs were still "highly stigmatised".
"Workers fear discrimination for taking leave for anything relating to their reproductive organs," Williams said.
"That shouldn't be the culture we accept."
12 days of paid Reproductive Health Leave (RHL) would cost an average of $3.6 billion to implement, but would save $1.88 billion for businesses directly.
These implementation costs are small in comparison to the annual $21.3 billion cost to businesses of lost productivity from workers having to manage reproductive health conditions.Sign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hamilton Spectator
3 hours ago
- Hamilton Spectator
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit . IPSEN CONTACTS Investors Khalid Deojee +33 6 66 01 95 26 Media Sally Bain +1 857 32 00 517 Anne Liontas +33 6 69 09 12 96 Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment


Business Upturn
3 hours ago
- Business Upturn
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product Officer is appointed to Andreas Gerber is appointed to EVP, Head of International is appointed to Caroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen's Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the International Region at Ipsen, Mari Scheiffele will now lead all medicines in Oncology and Rare Disease at Ipsen. In the new role, Mari will focus on driving product development and pipeline innovation for new medicines and lead globally, brands and life cycle management. Mari succeeds Bartek Bednarz who will now lead the newly created Asia, Pacific & China region at Ipsen. Andreas Gerber joins Ipsen from Johnson & Johnson where he most recently served as Worldwide Vice-president and Head of the Oncology Franchise. In his new role as Head of International, Andreas will lead Ipsen's operations in all geographies excluding North America. Andreas's extensive business acumen and commercial operations experience will support driving growth in Ipsen's three therapeutic areas: Oncology, Rare Disease and Neuroscience across the International region. Andreas succeeds Mari Scheiffele. Finally, Caroline Sitbon has been promoted to the role of Ipsen's General Counsel. Caroline joined the company from GSK in 2024 as Senior Vice President, Legal Affairs. In her new role, Caroline will lead legal and business ethics and will also serve as the Board of Directors' General Secretary. Caroline succeeds François Garnier who will be retiring after a very successful career, including his tenure as Ipsen's General Counsel and General Secretary to the Board of Directors. 'These three appointments bring additional highly qualified global leaders to our executive leadership team and I'm delighted that they represent a combination of internal promotions and new leaders that have joined Ipsen,' said David Loew, Chief Executive Officer. 'After personally working with both Mari and Caroline throughout their tenure at Ipsen, I have been impressed by their leadership, business insights and innovative mindsets. Each of these leaders, in their respective fields, have strongly contributed and partnered with Executive Leadership Team members to the ongoing transformation that we have been successfully driving at Ipsen. I am also very pleased to welcome Andreas to Ipsen. Over the last few years, I have observed his accomplishments and am convinced that his leadership and capacity to inspire our teams to execute and deliver on our strategy will be instrumental in our continuous growth trajectory in those respective markets. These additions also now represent a gender-balanced Executive Committee at Ipsen. I would also like to warmly thank François Garnier who had a long and distinguished career at Ipsen, making a big impact on the development of our company.' Mari Scheiffele said, 'I am honored to step into the role of Chief Product Officer at such an exciting time for our company. I am committed to driving innovation, fostering a culture of excellence, and continuing to work with our teams to deliver impact for our customers and patients.' Andreas Gerber said, 'I am thrilled to join Ipsen to lead the International Region and to work, together, with a world-class team to make a real impact on patients' everyday lives. I am looking forward to driving our innovative medicines across the portfolio to create access and adoption for patients and customers worldwide and to realize the full potential of our transformative therapies.' Caroline Sitbon added, 'It is an honor to take the General Counsel and General Secretary role and be part of this dynamic and fast-growing organization committed to advancing science for patients and consumers. I am very excited to have the opportunity to lead a highly qualified team that ensures our commitment to remain unwavering in compliance and integrity'. ABOUT IPSEN We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 80 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit . IPSEN CONTACTS Investors Khalid Deojee [email protected] +33 6 66 01 95 26 Media Sally Bain [email protected] +1 857 32 00 517 Anne Liontas [email protected] +33 6 69 09 12 96 Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on Attachment Ipsen PR_ELT Changes_23072025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


New York Post
16 hours ago
- New York Post
Expert reveals the secrets on how to get flawless sleep
A new report has revealed the extent of Australia's silent sleep epidemic, with one expert offering simple fixes for the nation's most common sleeping difficulties. The Great Aussie Wake-Up, commissioned by Holiday Inn Express, found that 91% of Australians struggle to fall or stay asleep in a typical week, and 93% regularly wake up too early. Sleep expert Olivia Arezzolo said the research showed the issue had progressed from a problem to a crisis. But she said three core controllable elements could be implemented to form the foundation for good sleep. 5 The Great Aussie Wake-Up found that 91% of Australians struggle to fall or stay asleep in a typical week. tonefotografia – 'When you look at the biomechanics of the circadian rhythm, there are key factors which control it,' she said. 'Light is one, eating is another, and temperature is another. Before adding the nice-to-haves, you need to get the essentials right first.' In terms of food, Arezzolo stressed the importance of having breakfast and warned against all too common late night snacking. 5 Three core controllable elements could be implemented to form the foundation for good sleep. fudio – 'I think a really big factor which is often overlooked, is there's this massive growth in intermittent fasting,' she said. 'It's one of the biggest trends of 2025 and this is meaning that a lot of Gen Z, but also just overall Aussies, are skipping breakfast. 'The stat from the Holiday Inn Express research was that 76% of Aussies are losing part of their morning routine and one in four are not eating breakfast. 'Breakfast is absolutely critical for circadian rhythm alignment. I'm sure you've heard that term with reference to light and temperature, but eating is also a regulator of the circadian rhythm. 5 'I think a really big factor which is often overlooked, is there's this massive growth in intermittent fasting,' she said. Antonioguillem – 'It essentially anchors the body clock. So in order to fall asleep with ease in the evening, we need to be having breakfast within the first hour of being awake.' Arezzolo said you ideally want three hours in between your last meal of the day and bedtime. For coffee it was a minimum of eight hours. 'I have a 2 p.m. absolute latest cut-off time (for coffee), but ideally, you want nothing after 12 o'clock, especially if you're struggling to sleep.' For light Arezzolo recommended getting 20 minutes of light within 30 minutes of waking and staying away from blue light producing screens close to bedtime. 'Like eating, light is a factor controlling the circadian rhythm. 'Essentially, if you're exposed to blue light in the evening, then you have the suppression of melatonin, which is your key sleep hormone to fall and stay asleep. 'This is akin to having a coffee before bed. As soon as you have that blue light enter your eyes, you have the biological signals to remain alert and awake.' 5 Arezzolo recommended getting 20 minutes of light within 30 minutes of waking and staying away from blue light producing screens close to bedtime. terovesalainen – Another key finding of the report was an over reliance on the snooze button with more than half (52%) of Australians hitting snooze every morning. Gen Z were among the worst offenders, with a massive 70% regularly hitting the button – and one in ten tapping snooze at least 120 times a month. 'When you're hitting the snooze button regularly, every time the alarm goes off, you get a spike in your stress hormone cortisol,' Arezzolo said. 'Too much cortisol leads to chronic states of anxiety, burnout, having that 'wired but tired feeling', being unable to sleep, and particularly 3 a.m. wakings. 'You're essentially setting your nervous system up to be on overdrive from the moment you wake up simply by pressing the snooze button, not just once, but multiple times. So that one is definitely alarming. Pardon the pun.' 5 Another key finding of the report was an over reliance on the snooze button with more than half (52%) of Australians hitting snooze every morning. highwaystarz – Arezzolo said in the course of her regular life, people are constantly asking her to fix their sleep however they tend to focus on alternative aids rather than focusing on the essentials. 'I'm like, 'okay, but tell me about your mornings and tell me about your evenings. What are you doing just before you're waking up and just before you're going to sleep? What are you doing just when you're waking up? Do you have the foundations right'? And nine times out of 10, they don't. 'You can't overlook these and then just pick and choose which sleep strategies you want to employ because you prefer that. It doesn't work like that. It's biology. 'Circadian rhythm is controlled by light, temperature and eating. So you have to get these things right.' Holiday Inn Express offers guests a free hot breakfast with every stay.